SLC5A2 and hydrops fetalis: Consistent with the EMPA-REG OUTCOME, CVD-REAL Study showed treatment with SGLT-2 inhibitors was associated with 39% relative risk reduction in HF hospitalization, a 51% reduction in all-cause mortality.